Yanqiu Q. Zhao

Harbin, 150001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Administering Bifidobacterium pseudolongum With Arsenic Trioxide Attenuates Acute Promyelocytic Leukemia in Mice by Restoring Immune Microenvironment and Intestinal Homeostasis.

Administering Bifidobacterium pseudolongum With Arsenic Trioxide Attenuates Acute Promyelocytic Leukemia in Mice by Restoring Immune Microenvironment and Intestinal Homeostasis.

Journal: Frontiers in bioscience (Landmark edition)

Published: November 26, 2025

T315I-mutated chronic myeloid leukemia with blast crisis relapse 10 years after allo-HSCT: A case report of second transplantation combined with olverembatinib maintenance therapy.

T315I-mutated chronic myeloid leukemia with blast crisis relapse 10 years after allo-HSCT: A case report of second transplantation combined with olverembatinib maintenance therapy.

Journal: Transplant immunology

Published: November 12, 2025

Clinical Characteristics, Molecular Analysis and Survival Outcomes of Patients With Extramedullary Acute Myeloid Leukemia: A Retrospective Single-Center Study.

Clinical Characteristics, Molecular Analysis and Survival Outcomes of Patients With Extramedullary Acute Myeloid Leukemia: A Retrospective Single-Center Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 25, 2025

Profound dFLC decrease after one cycle predicts superior outcome in patients with AL amyloidosis.

Profound dFLC decrease after one cycle predicts superior outcome in patients with AL amyloidosis.

Journal: Leukemia & lymphoma

Published: October 15, 2025

Combination of pre-transplant flow cytometry, WT1 expression, and NGS for MRD monitoring is potent in predicting the prognosis of AML receiving allogeneic transplantation.

Combination of pre-transplant flow cytometry, WT1 expression, and NGS for MRD monitoring is potent in predicting the prognosis of AML receiving allogeneic transplantation.

Journal: Annals of hematology

Published: March 17, 2025

Immune thrombotic thrombocytopenic purpura treated with Obinutuzumab: a case report and literature review

Immune thrombotic thrombocytopenic purpura treated with Obinutuzumab: a case report and literature review

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: March 03, 2025

Extramedullary relapse of acute lymphoblastic leukemia treated with a CAR-T cell therapy bridge to unrelated cord blood transplantation: a case report and review of the literature.

Extramedullary relapse of acute lymphoblastic leukemia treated with a CAR-T cell therapy bridge to unrelated cord blood transplantation: a case report and review of the literature.

Journal: Frontiers in oncology

Published: October 09, 2024

Early dFLC response by C1D7 predicts complete hematologic response in systemic AL amyloidosis.

Early dFLC response by C1D7 predicts complete hematologic response in systemic AL amyloidosis.

Journal: Annals of hematology

Published: September 08, 2024

Study on clinical features of early death in older patients with acute promyelocytic leukemia.

Study on clinical features of early death in older patients with acute promyelocytic leukemia.

Journal: Annals of hematology

Published: June 13, 2024

Efficacy and safety of first-line treatment with anti-CD38 monoclonal antibody-based regimen for primary plasma cell leukemia

Efficacy and safety of first-line treatment with anti-CD38 monoclonal antibody-based regimen for primary plasma cell leukemia

Journal: Zhonghua yi xue za zhi

Published: February 06, 2024

Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study.

Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study.

Journal: Hematology (Amsterdam, Netherlands)

Published: June 06, 2023

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML.

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML.

Journal: OncoTargets and therapy

Published: February 03, 2023

Showing 1-12 of 25

Last Updated: 09/26/2026